Page 588 - fbkCardioDiabetes_2017

564 Cardio Diabetes Medicine 2017

of intensive treatment of diabetes on the development and progression of ty communication—risk of heart failure. 2016. http://www.fda.gov/Safety/
long-term complications in insulin-dependent diabetes mellitus. N Engl J MedWatch/Safety Information /SafetyAlerts for Human Medical Products/
Med 1993;329: 977–986 ucm494252.htm.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose 24. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors
control with sulphonylureas or insulin compared with conventional treat- and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab
ment and risk of complications in patients with type 2 diabetes (UKPDS Cardiovasc Dis. 2014;24(7):689–97.
33). Lancet 1998;352: 837–853
25. Udell JA, et al. Glucose-lowering drugs or strategies and cardiovascular
5. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; AC- outcomes in patients with or at risk for type 2 diabetes: a metaanalysis of
CORD randomised controlled trials. Lancet Diabetes Endocrinol. 2015;3(5):356–
66.
6. Eye Study Group. Effects of medical therapies on retinopathy progression
in type 2 diabetes. N Engl J Med 2010;363: 233–244 26. Wu S, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular out-
comes: meta-analysis of randomized clinical trials with 55,141 partici-
7. American Diabetes Association. Standards of medical care in diabe- pants. Cardiovasc Ther. 2014;32(4):147–58.
tesd2010. Diabetes Care 2010; 33(Suppl. 1):S11–S61.
27. Li L, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in
8. Meinert C, Knatterud G, Prout T, Klimt CR. A study of the effects of hy- type 2 diabetes: systematic review and meta-analysis of randomised and
poglycemic agents on vascular complications in patients with adult-onset observational studies. BMJ. 2016;352:i610.
diabetes. II. Mortality results. Diabetes. 1970;19:789–830.
28. Fu AZ, Johnston S, Sheehan J, Ghannam A, Tsai K, Cappell K. Risk of
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors vs
blood-glucose control with metformin on complications in overweight pa- sulfonylureas and with saxagliptin vs sitagliptin in a US claims database.
tients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865. Diabetes. 2015;64(Suppl 1A):42.
10. Dormandy J, Charbonnel B, Eckland D et al. Secondary prevention of 29. Giorda CB, et al. Hospitalisation for heart failure and mortality associ-
macrovascular events in patients with type 2 diabetes in the PROactive ated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected
Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a population of subjects with type 2 diabetes: a nested case–control study.
randomised controlled trial. Lancet 2005;366:1279–1289. BMJ Open. 2015;5(6):e007959.
11. Wilcox R, Kupfer S, Erdmann E et al. Effects of pioglitazone on major 30. Ryden L, Shahim B, Mellbin L. Clinical implications of cardiovascular out-
adverse cardiovascular events in high-risk patients with type 2 diabetes: come trials in type 2 diabetes: from DCCT to EMPA-REG. Clin Ther.
results from PROspective pioglitAzone Clinical Trial In macro Vascular 2016;38(6):1279–87.
Events (PROactive 10). Am Heart J 2008;155:712–717.
31. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of
12. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other new medications for type 2 diabetes: time to reassess? Diabetes Care.
outcomes in dysglycemia. N Engl J Med 2012;367:319–328. 2016;39(5):738–42.
13. Scirica B, Bhatt D, Braunwald E et al. Saxagliptin and cardiovascular 32. Zannad F, et al. Assessment of cardiovascular risk of new drugs for the
outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 treatment of diabetes mellitus: risk assessment vs. risk aversion. EurHeart
;369:1317–1326.
J Cardiovasc Pharmacother. 2016;2(3):200–5.
14. White W, Cannon C, Heller S et al. Alogliptin after acute coronary syn- 33. Schnell O, et al. Report from the 1st cardiovascular outcome trial (CVOT)
drome in patients with type 2 diabetes. N Engl J Med 2013;369:1327– summit of the diabetes & cardiovascular disease (D&CVD) EASD study
1335. group. Cardiovasc Diabetol. 2016;15(1):33.
15. Green J, Bethel M, Armstrong P et al. Effect of Sitagliptin on Cardiovas- 34. An H, He L. Current understanding of metformin effect on the control of
cular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373:232–242. hyperglycemia in diabetes. J Endocrinol. 2016;228(3):R97–106.
16. Pfeffer M, Claggett B, Diaz R et al. Lixisenatide in Patients with Type 2 35. Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes,
Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247– 2015: a patient-centered approach: update to a position statement of
2257.
the American Diabetes Association and the European Association for the
17. Marso S, Daniels G, Brown-Frandsen K et al. Liraglutide and Cardiovas- Study of Diabetes. Diabetes Care. 2015;38(1):1409.
cular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311–322.
18. Marso S, Bain S, Consoli A et al. Semaglutide and Cardiovascular Outcomes
in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834–1844.
19. Zinman B, Wanner C, Lachin J et al. Empagliflozin, Cardiovascular Out-
comes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117–
2128.
20. FDA approves Jardiance to reduce cardiovascular death in adults with
type 2 diabetes. Available at www.fda.gov/NewsEvents/Newsroom/Pres-
sAnnouncements/ucm531517.htm.
21. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular
and renal events in type 2 diabetes. N Engl J Med. 2017.
22. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR,
Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, et al. Efficacy and
safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017.
23. FDA. Diabetes medications containing saxagliptin and alogliptin: drug safe-

GCDC 2017